The impact of generic form of clopidogrel on cardiovascular events in patients with coronary artery stent: Results of the OPCES study

Journal of Research in Medical Sciences

Volumn 16, Issue 5, 2011, Pages

  Khosravi, Ali Reza ^a,e   Pourmoqhadas, Masoud ^b   Ostovan, Mohammad ^c   Mehr, Gilda Kiani ^b   Gharipour, Mojgan ^b   Zakeri, Habib ^d   Soleimani, Bahram ^a   Namdari, Mehrdad ^f   Hassanzadeh, Mehdi ^g   Tavasolli, Ali Akbar ^b   Ghaffari, Samad ^h   Khaledifar, Arsalan ⁱ   Roghani, Farshad ^a   Khosravi, Mohammad Reza ^h   Sarami, Shahrooz ^j   Kojouri, Javad ^a   Nori, Fatemeh ^b   Khosravi, Elham ^a   Jozan, Mahnaz ^a   Sarrafzadegan, Nizal ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d FASA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e ISLAMIC AZAD UNIVERSITY   (Iran)

^f LORESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁱ SHAHREKORD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^j TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

more..

Author keywords

Cardiovascular events; Coronary artery stents; OPCES

Indexed keywords

CLOPIDOGREL; GENERIC DRUG; LIVER ENZYME; OSVIX; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; ARTICLE; BARE METAL STENT; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY STENT; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NEUTROPHIL COUNT; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK FACTOR; STABLE ANGINA PECTORIS; STENT THROMBOSIS; THROMBOCYTE COUNT;

EID: 79958037331     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348(9038): 1329-1339.
2. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102(6): 624-629.
3. Galla JM, Lincoff AM. The role of clopidogrel in the management of ischemic heart disease. Curr Opin Cardiol 2007; 22(4): 273-279.
4. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339(23): 1665-1671.
5. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308(6921): 81-106.
6. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCICURE study. Lancet 2001; 358(9281): 527-533.
7. Steinhubl SR, Berger PB, Mann JT, III, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288(19): 2411-2420.
8. Sarraf-Zadegan N, Sayed-Tabatabaei FA, Bashardoost N, Maleki A, Totonchi M, Habibi HR, et al. The prevalence of coronary artery disease in an urban population in Isfahan, Iran. Acta Cardiol 1999; 54(5): 257-263.
9. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293(17): 2126-2130.
10. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 297(2): 159-68.
11. Grines CL, Bonow RO, Casey DE, Jr., Gardner TJ, Lockhart PB, Moliterno DJ, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Catheter Cardiovasc Interv 2007; 69(3): 334-340.
12. Souri E, Jalalizadeh H, Kebriaee-Zadeh A, Shekarchi M, Dalvandi A. Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr 2006; 20(12): 1309-1314.
13. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985; 312(14): 932-936.
14. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115(17): 2344-2351.
15. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354(16): 1706-1717.
16. Tavazzi L. Clinical epidemiology of acute myocardial infarction. Am Heart J 1999; 138(2 Pt 2): S48-S54.
17. Kang DG, Jeong MH, Ahn Y, Chae SC, Hur SH, Hong TJ, et al. Clinical effects of hypertension on the mortality of patients with acute myocardial infarction. J Korean Med Sci 2009; 24(5): 800-6.
18. Alidoosti M, Salarifar M, Kassaian SE, Zeinali AH, Dehkordi MR, Fathollahi MS. In-hospital and late clinical outcomes of direct stenting strategy versus stenting after predilatation for the treatment of coronary artery lesions. Indian Heart J 2008; 60(4): 318-324.
19. Stone GW, Aronow HD. Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy. Mayo Clin Proc 2006; 81(5): 641-652.
20. Singh M, Rihal CS, Lennon RJ, Garratt KN, Holmes DR, Jr. Comparison of Mayo Clinic risk score and American College of Cardiology/American Heart Association lesion classification in the prediction of adverse cardiovascular outcome following percutaneous coronary interventions. J Am Coll Cardiol 2004; 44(2): 357-361.
21. Popma JJ, Leon MB, Moses JW, Holmes DR, Jr., Cox N, Fitzpatrick M, et al. Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation 2004; 110(25): 3773-3780.
22. Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999; 99(18): 2364-2366.
23. Gurbel PA, Kandzari DE. Stent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapy. Neth Heart J 2007; 15(4): 148-150.
24. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(7): 494-502.